| 1 |
Jerkic M, Szaszi K, Laffey JG, Rotstein O, Zhang H. Key Role of Mesenchymal Stromal Cell Interaction with Macrophages in Promoting Repair of Lung Injury. Int J Mol Sci 2023;24. [PMID: 36834784 DOI: 10.3390/ijms24043376] [Reference Citation Analysis]
|
| 2 |
Monte ER, O'Neill D, Abitorabi KM. A risk assessment study of SARS-CoV-2 propagation in the manufacturing of cellular products. Regen Med 2023;18:169-80. [PMID: 36453030 DOI: 10.2217/rme-2022-0096] [Reference Citation Analysis]
|
| 3 |
O'Kane CM, Matthay MA. Understanding the Role of Mesenchymal Stromal Cells in Treating COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2023;207:231-3. [PMID: 36194575 DOI: 10.1164/rccm.202209-1838ED] [Reference Citation Analysis]
|
| 4 |
Nova Z, Zemanek T, Botek N. Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. Int J Mol Sci 2022;23. [PMID: 36499448 DOI: 10.3390/ijms232315122] [Reference Citation Analysis]
|
| 5 |
Shirzad M, Nourigorji M, Sajedi A, Ranjbar M, Rasti F, Sourani Z, Moradi M, Mostafa Mir S, Memar MY. Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. Int Immunopharmacol 2022;111:109161. [PMID: 35998506 DOI: 10.1016/j.intimp.2022.109161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Huang Y, Li X, Yang L. Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment. Stem Cell Res Ther 2022;13:410. [PMID: 35962458 DOI: 10.1186/s13287-022-03034-4] [Reference Citation Analysis]
|
| 7 |
Lebeau G, Ah-pine F, Daniel M, Bedoui Y, Vagner D, Frumence E, Gasque P. Perivascular Mesenchymal Stem/Stromal Cells, an Immune Privileged Niche for Viruses? IJMS 2022;23:8038. [DOI: 10.3390/ijms23148038] [Reference Citation Analysis]
|
| 8 |
Chaudhary JK, Saini D, Chaudhary PK, Maurya A, Verma GK, Gupta AK, Roshan R, Vats TK, Garg N, Yadav D, Kant N, Meena AK, Mirza-shariff AA. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19. Cells 2022;11:2175. [DOI: 10.3390/cells11142175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 9 |
Dave JR, Chandekar SS, Behera S, Desai KU, Salve PM, Sapkal NB, Mhaske ST, Dewle AM, Pokare PS, Page M, Jog A, Chivte PA, Srivastava RK, Tomar GB. Human gingival mesenchymal stem cells retain their growth and immunomodulatory characteristics independent of donor age. Sci Adv 2022;8:eabm6504. [PMID: 35749495 DOI: 10.1126/sciadv.abm6504] [Reference Citation Analysis]
|
| 10 |
Kirkham AM, Monaghan M, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Cytotherapy 2022;24:639-49. [PMID: 35219584 DOI: 10.1016/j.jcyt.2021.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 11 |
Elisa L, Maria Antonietta A, Mirko B, Marco Z, Stefania C, Chiara V, Antonia M, Patrizia C. Acute respiratory distress syndrome secondary to Sars-COV-2 infection: treatment with mesenchymal stromal cells (mscs) to prevent pulmonary complications. JAHC 2022. [DOI: 10.36017/jahc2204-04] [Reference Citation Analysis]
|
| 12 |
Mallis P, Chatzistamatiou T, Dimou Z, Sarri EF, Georgiou E, Salagianni M, Triantafyllia V, Andreakos E, Stavropoulos-Giokas C, Michalopoulos E. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results. World J Biol Chem 2022; 13(2): 47-65 [DOI: 10.4331/wjbc.v13.i2.47] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Chutipongtanate S, Kongsomros S, Pongsakul N, Panachan J, Khowawisetsut L, Pattanapanyasat K, Hongeng S, Thitithanyanont A. Anti-SARS-CoV-2 effect of extracellular vesicles released from mesenchymal stem cells. J Extracell Vesicles 2022;11:e12201. [PMID: 35289102 DOI: 10.1002/jev2.12201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 14 |
Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04096-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 15 |
Behl T, Kaur I, Aleya L, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Bungau S. CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. Sci Total Environ 2022;808:152072. [PMID: 34863742 DOI: 10.1016/j.scitotenv.2021.152072] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 16 |
Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 2022;11:465. [DOI: 10.3390/cells11030465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Wu H, Huang C, Daga KR, Marklein RA, Ivanova N, Zeltner N. Human pluripotent stem cell-derived functional sympathetic neurons express ACE2 and RAAS components: a framework for studying the effect of COVID-19 on sympathetic responsiveness. Clin Auton Res. [DOI: 10.1007/s10286-021-00850-1] [Reference Citation Analysis]
|
| 18 |
John J, Ushakumary MG, Chandrasekher S, Chenicheri S. COVID-19 and acute myocardial injury: Stem cell driven tissue remodeling in COVID-19 infection. Stem Cells and COVID-19 2022. [DOI: 10.1016/b978-0-323-89972-7.00001-5] [Reference Citation Analysis]
|
| 19 |
Joy Thomas J, John J, Ushakumary MG. Stem cell-driven tissue regeneration as treatment for COVID-19. Stem Cells and COVID-19 2022. [DOI: 10.1016/b978-0-323-89972-7.00002-7] [Reference Citation Analysis]
|
| 20 |
Hardin LT, Xiao N. Stem Cells: A Promising Therapeutic Target for COVID-19. SCD 2022;12:1-27. [DOI: 10.4236/scd.2022.121001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 21 |
Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K, Elvers KT, Gamez M, Foster RR, Gillespie K, Hamilton F, Arnold D, Berger I, Davidson AD, Hill D, Caputo M, Madeddu P. The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond) 2021;135:2667-89. [PMID: 34807265 DOI: 10.1042/CS20210735] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 22 |
Arabpour E, Khoshdel S, Tabatabaie N, Akhgarzad A, Zangiabadian M, Nasiri MJ. Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:737590. [PMID: 34912818 DOI: 10.3389/fmed.2021.737590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 23 |
Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol 2021;164:69-82. [PMID: 34838588 DOI: 10.1016/j.yjmcc.2021.11.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 24 |
Generali M, Kehl D, Wanner D, Okoniewski MJ, Hoerstrup SP, Cinelli P. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. J Cell Mol Med 2021. [PMID: 34821008 DOI: 10.1111/jcmm.17048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 25 |
Sanie-Jahromi F, NejatyJahromy Y, Jahromi RR. A Review on the Role of Stem Cells against SARS-CoV-2 in Children and Pregnant Women. Int J Mol Sci 2021;22:11787. [PMID: 34769218 DOI: 10.3390/ijms222111787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Xu Z, Huang Y, Zhou J, Deng X, He W, Liu X, Li Y, Zhong N, Sang L. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Front Immunol 2021;12:738697. [PMID: 34659231 DOI: 10.3389/fimmu.2021.738697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L. Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis. Stem Cells Dev 2021;30:947-69. [PMID: 34416823 DOI: 10.1089/scd.2021.0179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 28 |
Fernández-Francos S, Eiro N, González-Galiano N, Vizoso FJ. Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives. Int J Mol Sci 2021;22:7850. [PMID: 34360616 DOI: 10.3390/ijms22157850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 29 |
Junwu W, Pengzhi S, Dong C, Shuguang W, Pingchuan W, Xinmin F, Liang Z. The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia: a systematic review and meta-analysis.. [DOI: 10.1101/2021.07.01.21259838] [Reference Citation Analysis]
|
| 30 |
Hernandez JJ, Beaty DE, Fruhwirth LL, Lopes Chaves AP, Riordan NH. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J Transl Med 2021;19:149. [PMID: 33853637 DOI: 10.1186/s12967-021-02813-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 31 |
Avanzini MA, Mura M, Percivalle E, Bastaroli F, Croce S, Valsecchi C, Lenta E, Nykjaer G, Cassaniti I, Bagnarino J, Baldanti F, Zecca M, Comoli P, Gnecchi M. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Transl Med 2021;10:636-42. [PMID: 33188579 DOI: 10.1002/sctm.20-0385] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 32 |
Avolio E, Carrabba M, Milligan R, Williamson MK, Beltrami AP, Gupta K, Elvers KT, Gamez M, Foster R, Gillespie K, Hamilton F, Arnold D, Berger I, Caputo M, Davidson AD, Hill D, Madeddu P. The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease.. [DOI: 10.1101/2020.12.21.423721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
